I foresee this company tipping the scale over $100.00 per share
I just see it realistically. This is one freeking awesome drug and hematologist and oncologist can't wait until it gets approved. Patients can't wait until the next clinical trial. This will be far better than gleevec. Pharmacyclics nees to hand over the the reigns to JNJ we want to keep this drug a going concern for all those people who will have to depend on it. I can only hope Duggan has brains enough to not think he is a Pharma God. Put the drug in company hands who can put it to best use.